Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 6 months to \< 10 years~2. Confirmed diagnosis of beta-thalassemia, as determined by high performance liquid chromatography (HPLC) or DNA testing~3. Started on a red blood cell (RBC) transfusion regimen, with a minimum of 2 transfusions already completed~4. Screening level of serum ferritin (SF) greater than \>200 μg/L but not more than 600 μg/L. Since SF level may be impacted by the presence of infection, it must additionally be verified that the child has had no signs of infection in the previous 7 days, including the day of screening, and that the level of C-reactive protein (CRP) is no greater than 20% higher than the normal range for the patient's age. If there are signs of infection and/or the CRP level is above this threshold, the SF level must be checked again a minimum of one week later.~Exclusion Criteria:~1. Prior use of iron chelation~2. Diagnosis of hepatitis B or C, or HIV infection~3. Evidence of abnormal liver or kidney function at screening: serum alanine transaminase (ALT) level \> 5 times upper limit of normal or creatinine levels \>2 times upper limit of normal~4. Disorders associated with neutropenia (absolute neutrophil count \< 1.5 x 10\^9/L) prior to the initiation of study medication~5. A serious, unstable illness, as judged by the investigator, during the previous 3 months before screening/baseline visit including but not limited to hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease.~6. Presence of any medical condition which in the opinion of the investigator would cause participation in the study to be unwise.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Deferiprone (Type: EXPERIMENTAL): Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses

Based on this trial design, predict the completion outcome and termination type (if applicable).